These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 31555219)
1. Gut Dysfunction and Non-alcoholic Fatty Liver Disease. Grabherr F; Grander C; Effenberger M; Adolph TE; Tilg H Front Endocrinol (Lausanne); 2019; 10():611. PubMed ID: 31555219 [TBL] [Abstract][Full Text] [Related]
2. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205 [TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver and the gut microbiota. Bashiardes S; Shapiro H; Rozin S; Shibolet O; Elinav E Mol Metab; 2016 Sep; 5(9):782-94. PubMed ID: 27617201 [TBL] [Abstract][Full Text] [Related]
4. Gut microbiota, fatty liver disease, and hepatocellular carcinoma. Chu H; Williams B; Schnabl B Liver Res; 2018 Mar; 2(1):43-51. PubMed ID: 30416839 [TBL] [Abstract][Full Text] [Related]
5. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642 [TBL] [Abstract][Full Text] [Related]
6. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Zhou J; Tripathi M; Sinha RA; Singh BK; Yen PM Hepatoma Res; 2021; 7():11. PubMed ID: 33490737 [TBL] [Abstract][Full Text] [Related]
7. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC. Song Q; Zhang X Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327326 [TBL] [Abstract][Full Text] [Related]
8. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Chu H; Duan Y; Yang L; Schnabl B Gut; 2019 Feb; 68(2):359-370. PubMed ID: 30171065 [TBL] [Abstract][Full Text] [Related]
9. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota. Han R; Ma J; Li H Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233 [TBL] [Abstract][Full Text] [Related]
10. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease. Ni Y; Ni L; Zhuge F; Fu Z Mol Nutr Food Res; 2020 Sep; 64(17):e2000375. PubMed ID: 32738185 [TBL] [Abstract][Full Text] [Related]